Abstract
Tuberculosis is an important public health problem and the second leading cause of death worldwide, killing nearly 2 million people each year. Pulmonary tuberculosis will continue to be a major killer and a constant threat in Korea, too. The definitive diagnosis of pulmonary tuberculosis is established based on a culture positive for Mycobacterium tuberculosis, but rapid diagnosis of infectious tuberculosis by simple sputum smear for acid-fast bacilli remains an important tool, and more robust molecular techniques are of promise. The two main goals of the treatment of tuberculosis are to cure the individual patients and to minimize the transmission of Mycobacterium tuberculosis to other persons. Treatment with several drugs for 6 months or more can cure the disease in more than 95% of cases. Systematic monitoring of treatment outcomes is essential to effective treatment of pulmonary tuberculosis. The proportion of patients diagnosed and treated effectively has increased greatly over the past decade but is still far short of global targets. Multi-drug resistant tuberculosis poses a growing threat to the global tuberculosis control. Recent advances in microbial genetics and host immunity can provide an opportunity for renewed investigation of this persistent threat to the human health.
Figures and Tables
Table 3
*All drugs can be given daily or intermittently(3/week throughout or twice/week after the initial phase of daily therapy).
†Regimen is tailored according to the results of drug susceptibility tests.
‡Streptomycin treatment should be discontinued after 2 months.
§Amikacin, kanamycin, or capreomycin. Treatment with all of these agents should be discontinued after 2~6 months, depending upon the patient's tolerance and response.
Q, quinolone; PAS, para-aminosalicylic acid.
References
2. Stewart GR, Robertson BD, Young DB. Tuberculosis: a problem with persistence. Nat Rev Microbiol. 2003. 1:97–105.
3. Wolff AJ, O'Donnell AE. HIV-related pulmonary infections: a review of the recent literature. Curr Opin Pulm Med. 2003. 9:210–214.
4. Lambert ML, Hasker E, Van Deun A, Roberfroid D, Boelaert M, Van der Stuyft P. Recurrence in tuberculosis: relapse or reinfection? Lancet Infect Dis. 2003. 3:282–287.
5. Bastian I, Stapledon R, Colebunders R. Current thinking on the management of tuberculosis. Curr Opin Pulm Med. 2003. 9:186–192.
6. Hong YP, Kim SJ, Lew WJ, Lee SH, Lee EK. Cohort analyses of the treatment of smear positive pulmonary tuberculosis patients under programme conditions in Korea, 1983-1994. Int J Tuberc Lung Dis. 1998. 2:365–371.
10. Eichbaum Q, Rubin EJ. Tuberculosis. Advances in laboratory diagnosis and drug susceptibility testing. Am J Clin Pathol. 2002. 118:Suppl. S3–S1.
11. Schoch OD, Pfyffer GE, Buhl D, Paky A. False-positive Mycobacterium tuberculosis culture revealed by restriction fragment length polymorphism analysis. Infection. 2003. 31:189–191.
14. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. Treatment of Tuberculosis. Am J Respir Crit Care Med. 2003. 167:603–662.
15. Tobin MJ. Tuberculosis, lung infections, interstitial lung disease, social issues and journalology in AJRCCM 2003. Am J Respir Crit Care Med. 2004. 169:288–300.
18. Raviglione MC, O'Brien RJ. Braunwald E, editor. Tuberculosis. Principles of Internal Medicine. 2001. 15th ed. New York: McGraw-Hill;1024–1034.